ANAPTYSBIO, INC — Director's Dealing 2021

Feb 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANAPTYSBIO, INC (ANAB)
CIK: 0001370053
Period of Report: 2021-02-10

Reporting Person: LOUMEAU ERIC J (COO, General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-12	Common Stock	M	10000	$14.02	Acquired	10000	Direct
2021-02-12	Common Stock	S	10000	$35.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-10	Stock Option (right to buy)	$29.70	A	45000	Acquired	2031-02-09	Common Stock (45000)	Direct
2021-02-12	Stock Option (right to buy)	$14.02	M	10000	Disposed	2029-12-08	Common Stock (10000)	Direct

Footnotes

F1: The transaction reported on this Form 4 were effected pursuant to a Rule 105b-1 trading plan adopted by the reporting person.

F2: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F3: The stock option vested as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F4: In addition to the remaining option to purchase 88,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 147,500 shares of common stock, which options vest according to their terms.